McMaster University spin-off company Fusion Pharmaceuticals and superconducting accelerator technology firm Niowave have inked a $5 million supply agreement for the development, production, and supply of actinium-225.
The cash will support Niowave's efforts to increase its production of actinium-225. As part of the deal, Fusion will have guaranteed access to a predetermined percentage of the radiopharmaceutical as well as preferred access to any excess supply.
Fusion is developing actinium-based targeted alpha therapy. Actinium-225 decay kills tumor cell DNA, it said. The company already has existing agreements with Canadian particle accelerator center TRIUMF and the U.S. Department of Energy.
![A 53-year-old patient (patient number four) with a recurrent pituitary adenoma with extension of a cystic component of disease to the medial temporal lobe apparent on MRI (contoured in blue), and extension of disease to the left sphenoid bone and orbital apex apparent on [68Ga]Ga-DOTA-TATE (contoured in yellow).](https://img.auntminnie.com/mindful/smg/workspaces/default/uploads/2026/04/pituitary-tumor.QGsEnyB4bU.jpg?auto=format%2Ccompress&dpr=2&fit=crop&h=167&q=70&w=250)
